OrbiMed Advisors

Avenzo Therapeutics is committed to improving the lives of cancer patients by developing next-generation oncology therapies that address high unmet medical needs.

ADARx is a clinical-stage biotechnology company dedicated to transforming cutting-edge science into next-generation RNA therapeutics to treat a broad spectrum of diseases. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.

Caris Life Sciences is a precision medicine pioneer that utilizes molecular profiling and artificial intelligence to revolutionize cancer care and improve patient outcomes through personalized treatment options.

Adaptive Biotechnologies is harnessing the power of the adaptive immune system to transform how diseases are detected, monitored, and treated through innovative diagnostics and therapeutics.

Adicet Bio is focused on developing best-in-class gamma delta T cell therapies for patients battling autoimmune diseases and cancer, utilizing a novel platform for allogeneic CAR T cell therapies.

Aer Therapeutics is a clinical-stage biopharmaceutical company developing a therapeutic solution for muco-obstructive lung diseases, specifically targeting mucus obstruction in patients with COPD and asthma.

AirStrip provides mobile-first clinical surveillance and alarm communication management technology that unlocks siloed clinical data and transforms it into contextually rich information to surface life-saving decisions that need to be made now.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.

MBX Capital is a venture capital fund with a "deep health" thesis that treats health as a systems problem. They invest across biology, chemistry, AI/ML, robotics, and clinical medicine to back companies addressing root causes of environmental health and healthcare infrastructure challenges. The fund makes $1–2.5M first checks targeting ≥5% equity and operates with a private "Atom Network" of hundreds of scientific and clinical experts who help source and vet investments.

Digital health venture capital firm focused on companies enabling new care delivery models or more efficient therapeutic development.

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.